DiaMedica Therapeutics (NASDAQ:DMAC – Get Free Report) released its quarterly earnings data on Monday. The company reported ($0.18) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.17) by ($0.01), Zacks reports.
DiaMedica Therapeutics Stock Performance
Shares of NASDAQ DMAC opened at $5.21 on Wednesday. The firm’s 50 day moving average price is $5.95 and its 200-day moving average price is $5.10. The company has a market cap of $222.78 million, a PE ratio of -9.30 and a beta of 1.52. DiaMedica Therapeutics has a 52-week low of $2.14 and a 52-week high of $6.82.
Analyst Ratings Changes
Separately, HC Wainwright boosted their price objective on shares of DiaMedica Therapeutics from $7.00 to $10.00 and gave the company a “buy” rating in a research report on Wednesday.
DiaMedica Therapeutics Company Profile
DiaMedica Therapeutics Inc, a clinical stage biopharmaceutical company, focuses on improving the lives of people suffering from serious diseases with a focus on acute ischemic stroke. Its lead candidate is DM199, a pharmaceutically active recombinant form of the human tissue kallikrein-1 protein, which is in Phase II/III trials for the treatment of acute ischemic stroke, as well as that is in Phase 2 to treat cardio-renal disease.
Featured Stories
- Five stocks we like better than DiaMedica Therapeutics
- What is the S&P/TSX Index?
- 3 Stocks Returning Billions to Shareholders via Buybacks
- How to Start Investing in Real Estate
- Tesla: 1 Reason to Love It, 1 Reason to Be Cautious
- What is the Euro STOXX 50 Index?
- 3 Stocks That Could Win Big From a 10% Cap on Credit Card Rates
Receive News & Ratings for DiaMedica Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DiaMedica Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
